BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 35677992)

  • 1. Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development.
    Kast J; Nozohouri S; Zhou D; Yago MR; Chen PW; Ahamadi M; Dutta S; Upreti VV
    Clin Transl Sci; 2022 Sep; 15(9):2057-2074. PubMed ID: 35677992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacology Perspectives for Adoptive Cell Therapies in Oncology.
    Huang W; Li J; Liao MZ; Liu SN; Yu J; Jing J; Kotani N; Kamen L; Guelman S; Miles DR
    Clin Pharmacol Ther; 2022 Nov; 112(5):968-981. PubMed ID: 34888856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.
    Hiltensperger M; Krackhardt AM
    Front Immunol; 2023; 14():1121030. PubMed ID: 36949949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies.
    Zhao D; Zhu D; Cai F; Jiang M; Liu X; Li T; Zheng Z
    Technol Cancer Res Treat; 2023; 22():15330338231204198. PubMed ID: 38037341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry Perspective.
    Mody H; Ogasawara K; Zhu X; Miles D; Shastri PN; Gokemeijer J; Liao MZ; Kasichayanula S; Yang TY; Chemuturi N; Gupta S; Jawa V; Upreti VV
    Clin Pharmacol Ther; 2023 Sep; 114(3):530-557. PubMed ID: 37393588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
    Abramson JS; Lunning M; Palomba ML
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.
    Kandra P; Nandigama R; Eul B; Huber M; Kobold S; Seeger W; Grimminger F; Savai R
    Front Immunol; 2022; 13():903562. PubMed ID: 35720364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of CAR T cell in malignancies: A scoping review.
    Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
    Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
    Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
    Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
    Maus MV; Levine BL
    Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy.
    Cortés-Selva D; Dasgupta B; Singh S; Grewal IS
    Trends Pharmacol Sci; 2021 Jan; 42(1):45-59. PubMed ID: 33250273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023.
    Sun MY; Li W; Chen W
    Hum Vaccin Immunother; 2023 Aug; 19(2):2251839. PubMed ID: 37814513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer.
    Lundh S; Jung IY; Dimitri A; Vora A; Melenhorst JJ; Jadlowsky JK; Fraietta JA
    Clin Exp Med; 2020 Nov; 20(4):469-480. PubMed ID: 32333215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.
    Zhang E; Xu H
    J Hematol Oncol; 2017 Jan; 10(1):1. PubMed ID: 28049484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects.
    Shafer P; Kelly LM; Hoyos V
    Front Immunol; 2022; 13():835762. PubMed ID: 35309357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
    Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
    Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control.
    Lu L; Xie M; Yang B; Zhao WB; Cao J
    Sci Adv; 2024 Feb; 10(8):eadj6251. PubMed ID: 38394207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.